Preview

Научно-практическая ревматология

Расширенный поиск

Качество жизни как критерий эффективности терапии базисными противовоспалительными и генноинженерными препаратами: результаты международных и российских исследований

https://doi.org/10.14412/1995-4484-2009-460

Полный текст:

Список литературы

1. <div><p>Sacks J.J., Helmick C.G., Langmaid G. Deaths from arthritis and other rheumatic conditiones, United States, 1979-1998. J.Rheumatology, 2004, 31, 1823- 28</p><p>Lee D.V.,Weinblatt M.E. Rheumatoid arthrinis. Lancet, 2001, 358, 903-11</p><p>Mili F.,Helmick C.G.,Moriarty D.G. Health related quality of life among adults reporting arthritis: analysis of data from the Behavioral Risk Factor Surveillance System, US,1996-99. J.Rheumatol., 2003, 30, 160-6</p><p>Felson D.T., Anderson J.J., Boers M.et al. The American College of Rheumatology preliminary core of disease activity measures for rheumatoid arthritis clinical trails. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum., 1993, 36, 729-40.</p><p>Fries J.F., Spitz P., Kraines R.G., Holman H.R. Measurement of patient outcome in arthtitis. Arthritis Rheum.,1980,23, 2, 137-45.</p><p>Ware J. E., Snow K.K., Kosinski M., Gandek B. Sf-36 Health Survey. Manuel and Interpretation Guide. Lincoln, RI :Quality Metric Incorporated, 2000, 150.</p><p>Brooks R. with the EuroQol Group. EuroQol: the current state of play. Health Policy, 1996, 37, 53-72.</p><p>Strand V., Singh J.A. Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials. Am.J.Managed Care, 2008, 4, 14, 239-53</p><p>Uhlig T., Haavardsholm E.A., Kvien T.K. Comparison of the Health Assessment Questionnaire (HAQ) and the modified HAQ-DI in patients with rheumatoid arthritis. Rheumatology, 2006, 45, 454-58</p><p>Hakkinen A., Kautianen H., Hannonen P., et al.Muscle strength, pain, and disease activity explain individual subdimensiones of the HAQ index,especially in women with rheumatoid arthritis. Ann.Rheum.Dis., 2006, 65, 30-34</p><p>Scott D.L., Smith C., Kingsley G. Joint damage and disability in rheumatoid arthritis: an updated systematic review. Clin.Exp.Rheumatol., 2003,21 (suppl 31), 20-27</p><p>West E., Jonsson S.W. Health related quality of life in rheumatoid arthritis in Northen Sweden: a comparison between patients with early RA, patients with medium-term disease and controls, using SF-36. Clin.Rheumatol.,2005,24,117-22</p><p>Cohen S., Stand V.,Aguilar D., Ofman J.J. Patient versus physician-reported outcomes in rheumatoid arthritis patients treated with recombinant interleukin-1receptor antagonist (anakinra) therapy. Rheumatology,2004,43,704-11</p><p>Strand V., Pincus T. The HAQ provides a single effective measure to discriminate active from placebo treatment in randomized controlled trials in rheumatoid arthritis. Arthritis Rheum., 2003, 48, 3656 Abstr.LB 6</p><p>Амирджанова В.Н. Оценка эффективности терапии больных ревматоидным артритом по показателям качества жизни. Науч.-практ.ревматол., 2007,5,93-9</p><p>Tugwell P., Wells G., Maetzel A et al.Leflunomide Rheumatoid Arthritis Investigators Group.Clinical improvement as reflected in measures of functional and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensivity and relative efficiency to detect a treatment effect in twelve-month, placebo-controlled trial. Arthritis Rheum.,2000,43, 506-14.</p><p>Kosinski M., Zhao S.Z., Dedhiya S et al.Determining minimally important changes in general and disease- specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthr. Rheum.,2000, 43, 7, 1478-87.</p><p>Strand V., Bombardier C., Naetzel A et al. Use of minimum clinically important differences in evaluating patient responses to treatment of RA. Arthritis Rheum. (suppl.), 2001,44, S187</p><p>Амирджанова В.Н.,Горячев Д.В., Коршунов Н.И. с соав. Популяционные показатели качества жизни по опроснику SF-36 (результаты многоцентрового исследования качества жизни «МИРАЖ»). Научно-практ. ревматол., 2008,1,36-48</p><p>Osiri M.,Shea B., Robinson V. et al. Leflunomide for the treatment of rheumatoid arthritis: a systemic review and metaanalysis. J. Rheumatol., 2003,30,1183-90</p><p>Strand V., Tugwell P., Bombardier C. for the Leflunomide Rheumatoid Arthritis Investigation Group. Function and health-related quality of life: results from a randomized, controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis.Arthritis Rheum.,1999,42,1870- 78</p><p>Strand.V., Scott D.L., Emery P. for the Leflunomide Rheumatoid Arthritis Investigation Group.Physical function and health-related quality of life:analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine,or methotrexate in patients with active rheumatoid arthritis.J.Rheumatol.,2005,3 2,590-601</p><p>Strand V., Cohen S., Schiff M. for the Leflunomide Rheumatoid Arthritis Investigation Group. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch.Intern.Med., 1999,159,2542-50</p><p>Lipsky P.E., van der Heijde D.M.,St Clair E.W., for the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis With Concominant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N.Engl.J.Med.,2000, 343, 1594-1602</p><p>Klareskog L., van der Heijde D.M., de Jager J.P. for the TEMPO Study Investigation. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomized controlled trial. Lancet,2004,363, 675-681</p><p>Strand V., Weinblatt M., Keystone E. Treatment with adalimumab (D2E7), a fully human anti-TNF moboclonal antibody, improves physical function and health-related quality of life in patients with active rheumatoid arthritis. Ann.Rheum.Dis.,2002,61,S175</p><p>Durez P., Nzeusseu Toukap A.,Lauwerys B.R. A randomized comparative study of short term clinical and biological effects of intravenous pulse methylprednisolone and infliximab in patients with active rheumatoid arthritis despite metotrexate treatment. Ann.Rheum.Dis.,2004,63,1069-1074</p><p>Maini R.N.,Breedveld F.C., Kalden J.R. for the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis With Concominant Therapy Study Group. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum., 2004,50,1051-65</p><p>Kavanaugh A., Han C., Bala M. Functional status and radiographic joint damage are associated with health economic outcomes in patients with rheumatoid arthritis. J.Rheumatol., 2004, 31, 849-55</p><p>Han C., Smolen J., Kavanaugh A. et al. The impact of infliximab treatment on quality of life in patients with inflammatory rheumatic diseases. Arthritis Res.Ther., 2007, 9, R103</p><p>St.Clair E.W., van der Heijde D.V., Smolen J.S. et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: randomized,controlled trial. Arthritis Rheum., 2004, 50, 3432-43</p><p>Smolen J.S., Han C., Bala M. et al. Patients with early rheumatoid arthritis achieved a clinically meaningful and sustained improvement in physical function after treatment with infliximab. Ann. Rheum. Dis., 2005, 64 (suppl. III), 418.Abstract SATO031</p><p>Cohen J.D., Zaltni S., Kaiser M.J. et al. Secondary addition of methotrexate to partial responders to etanercept alone is effective in severe rheumatoid arthritis. Ann. Rheum. Dis., 2004,63,209-10</p><p>Moreland L.W., Baumgartner S.W., Schiff M.H. et al. Treatment of rheumatoid arthritis with a recombinant humor necrosis factor receptor (p75)-Fc fusion protein. N.Engl.J.Med., 1997,337, 141-7</p><p>Moreland L.W., Schiff M.N., Baumgartner S.W. et al. Etanercept therapy in rheumatoid arthritis: random- ized, controlled trial. Ann.Intern.Med.,1999,130,478-86</p><p>Weinblatt M.E., Kremer J.M., Bankhurst A.D. et al. A trial of etanercept, a recombinant tumor necrosis factor receptor; Fc fusion protein, in patients with rheumatoid arthritis receiving metotrexate. N.Engl.J.Med., 1999,340,253-9</p><p>Сигидин Я.А., Лукина Г.В. Биологическая терапия в ревматологии. М., Издательство « Новости», 2007,179 с</p><p>Weinblatt M.E., Keystone E.C., Furst D.E. et al Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum., 2003,48,35-45</p><p>Van de Putte L., Atkins C., Malaise M. et al. Sustained 5-year efficacy of adalimumab (HUMIRA) monotherapy in DMARD-refractory rheumatoid arthritis (RA). Arthritis Rheum., 2003, 48, 9, suppl. (S314)</p><p>Breedveld F.C., Weisman M.N., Kavanaugh A.F. et al. The RPEMIER Study. A multicenter, randomized, double-blind clinical study of combination therapy with adalimumab and methotrexate versus methotrexate alone or adalimumab alone in patients with early,aggressive rheumatoid arthritis who had not previous methotrexate therapy. Arthritis Rheum., 2006, 54, 26-37</p><p>Torrance G.W.,Tugwell P., Amorosi S. et al. Imrpovement in health utility among patients with 6rheumatoid arthritis treated with adalimumab (a human anti-TNF monoclonal antibody) plus methotrexate. Rheumatology (Oxford), 2004,43,712-18</p><p>Keystone E.C., Kavanaugh A.F., Sharp J.T. et al. Radiographic,clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients in patients with active rheumatoid arthritis receiving concominant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum., 2004,50, 1400-11</p><p>van der Heijde D.V., Klareskog L., Singh A. et al.Рatients reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial. Ann. Rheum. Dis.,2006,65,328-34</p><p>Mittendorf T., Dietz B., Sterz R. et al.Von der Schulenberg J.M. Improvement and long-term maintenance of quality of life during treatment with adalimumab in severe rheumatoid arthritis. J.Rheumatol., 2007, 34, 2343-50</p><p>Burmester GR, et al. . Adalimumab effective and safe in treating RA in real life clinical practice: Final summary of the 6610 patients in REACT study. EULAR 2006, Amsterdam, THU0213</p><p>Strand V. et al. Adalimumab improves Health-related Quality of life in rheumatoid arthritis patients. EULAR 2003, SAT 0246</p><p>Kimel M., Cifaldi M., Chen N., Revicki D. Adalimumab plus methotrexate improved SF-36 scores and reduced the effect of rheumatoid arthritis (RA) on work activity for patients with early RA. J.Rheumatol., 2008, 35, 2 ,206-15</p><p>Bejarano V. Improved work stability and reduced job loss with adalimumab plus methotrexate in early rheumatoid arthritis: Results of the prevention of work disability (PROWD) study.Ann.Rheum.Dis.,2007, 2, 66, suppl.2 (176) , THU0167.</p><p>Kievit W., Adang EM., Fransen J. et al. The effectiveness and medication costs of three antitumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data. Ann. Rheum. Dis., 2008, 67(9), 1229-34</p><p>Genovese M.C., Becker J.C., Schiff M. et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alfa ingibition. N.Engl.J.Med., 2005, 353,1114- 23</p><p>Kremer J.M., Genant H.K., Moreland L.W.et al. Effects of abatacept in patients with methonrexate- resistent active rheumatoid arthritis : a randomized trial. Ann. Intern. Med., 2006, 144, 865-76</p><p>Russell A.S., Wallenstein G.V., Li T. et al. Abatacept improves both the phisical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment. Ann.Rheum. Dis.,2007, 66, 189-94</p><p>Westhovens R., Cole J.C., Li T. et al. Improvement health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in double-blind, placebo- controlled, multicentre randomized clinical trial. Rheumatology (Oxford),2006,45,1238-46</p><p>Weinblatt M., Combe B., Covucci A. et al. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized,placebo- controlled study. Arthritis Rheum.,2006,54,2807-16</p><p>Edwards J.C., Szczepanski L., Szczechinski J.et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N.Engl.J.Med., 2004,350,2572-81</p><p>StrandV., Balbir-Gurman A., Pavelka K. et al. Sustained benefit in rheumatoid arthritis following one course of rituximab: improvement in phisical function over 2 years. Rheumatology (Oxford), 2006,45,1506-13</p><p>Emery P.,Fleishmann R.,Filipowich-Sosnowska A. et al. for the DANCER study group. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment. Results of a phase IIb randomized, double-blind, placebo-controlled doserange trial. Arthritis Rheum.,2006,54,1390-1400</p><p>Cohen S.B.,Emery P.,Greenwald M.W. et al. foe the REFLEX Trial Group. Rituximab for the rheumatoid arthritis refractory to anti-tumor necrosis factor therapy.Results of multicenter, randomized, double- blind, placebo-controlled , phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum.,2006,54,2793-2806.</p><p>Kielhom A., Bombardieri S., Aultman R et al. Rituximab improves health-related quality of life as measured by the SF-36: domain score results from the REFLEX study. Ann. Rheum. Dis., 2006,65 (suppl. 2),324)</p></div><br />


Для цитирования:


Amirdjanova V.N., Kaigorodtseva E.Y., Savenkova N.A., Насонов Е.Л. Качество жизни как критерий эффективности терапии базисными противовоспалительными и генноинженерными препаратами: результаты международных и российских исследований. Научно-практическая ревматология. 2009;47(2):54-66. https://doi.org/10.14412/1995-4484-2009-460

For citation:


Amirdjanova V.N., Kaigorodtseva E.Y., Savenkova N.A., Nasonov E.L. Quality of life as a criterion of disease modifying anti-rheumaticdrug and biological agents therapy efficacy: results of international and Russian studies. Rheumatology Science and Practice. 2009;47(2):54-66. (In Russ.) https://doi.org/10.14412/1995-4484-2009-460

Просмотров: 370


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)